[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"German Heart Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":136},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,57,91,115],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100607172","determination-of-the-prevalence-of-unrecognized-heart-failure-among-patients-at-risk-in-urban-areas-across-germany-using-cmr-100607172",false,"NCT07185100","Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR","A Prospective, Cross-sectional, Nationwide Community-based Observational Study to Determine the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR","WE-CARE-HF-CMR","Inclusion Criteria:\n\nAsymptomatic subjects with:\n\n* chronic diabetes mellitus (known\u002Fdiagnosed and\u002For antidiabetic medication and\u002For elevated HbA1C) and\u002For\n* renal impairment (known\u002Fdiagnosed CKD and\u002For in laboratory CKD III° or higher) and\u002For\n* Hypertension (known\u002Fdiagnosed and\u002For antihypertensive medication\u002Ftreatment) and\u002For\n* Hypercholesterolaemia (known\u002Fdiagnosed and\u002For antilipid medication\u002Ftreatment) and\u002For\n* Obesity (known\u002Fdiagnosed and\u002For BMI \\> 30 (kg\u002Fm²)) and\u002For\n* Smoker (known\u002Fdiagnosed and\u002For current\u002Fprevious and\u002For medication\u002Ftreatment)\n* Age 40-69 years\n* female or male or diverse sex\n* Ability to provide informed consent\n* Provision of Informed Consent\n\nExclusion Criteria:\n\n* Inability to provide written informed consent\n* Diagnosed heart failure or previously detected reduced ejection fraction\n* General MRI exclusion criteria (pacemaker, defibrillator, intracranial aneurysm clips, metallic foreign bodies in the eyes)\n* Any MRI exclusion criteria not listed here, as determined by the MRI laboratory performing the procedure\n* Haemodynamically unstable participants (heart rate \\\u003C 45\u002Fmin, systolic blood pressure \\\u003C 90 mmHg)\n* Claustrophobia\n* Sensorineural hearing loss of 30 dB or more and tinnitus\n* Acute mental disorders requiring therapy\n* In the presence of pregnancy","ALL","40 Years","69 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities\u002Fmetropol areas in Germany ( \\> 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas.\n\nThe results of the study will be compared with the results from the \"HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).",[26,27,28],"Heart Failure With Preserved Ejection Fraction (HFPEF)","Renal Dysfunction","Stage B Heart Failure",[30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Prevention","Heart failure","HFpEF","Asymptomatic","Cardiology","Urban area","Germany","CMR","Cardiac Magnetic Resonance","HFrEF","Diastolic Dysfunction","Strain","mobile","GLS","RECRUITING","2026-03-26",{"date":47,"type":48},"2026-04-01","ACTUAL",{"date":50,"type":48},"2025-09-13",{"date":52,"type":22},"2036-12-31",{"name":54,"class":55},"German Heart Institute","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100617587","personalized-atrial-fibrillation-ablation-guided-by-non-invasive-global-mapping-100617587","NCT07320560","Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping","Personalized Atrial Fibrillation Ablation Guided by Non-Invasive Global Mapping - the CURE-AF Pilot Study","CURE-AF","Inclusion Criteria:\n\nAblation-naïve patients with:\n\n1. Persistent AF planned for catheter ablation plus\n2. Left atrial enlargement (LA diameter ≥45 mm or LA volume index ≥35ml\u002Fm2 or LA area ≥20 cm2)\n\nExclusion Criteria:\n\n* Previous cardiac ablation\n* Age \\\u003C18 years\n* Pregnancy or lactation\n* Previous stroke\u002FTIA\n* Severe left ventricular dysfunction (LVEF \\\u003C35%)\n* Renal failure (GFR \\\u003C30 ml\u002Fmin)\n* Dermal disease or hypersensitivity predisposing for skin irritation or exanthema","18 Years",{"count":67,"type":22},45,"INTERVENTIONAL",[70],"NA","This pilot study investigates if non-invasive global mapping can guide catheter ablation of atrial fibrillation (AF) by defining personalized targets based on the temporal Stability of local Atrial High-Rate Activity (SAHRA). The study also assesses efficacy and safety of this approach and evaluates potential signals of harm. The main questions it aims to answer are:\n\n* Does ablation of targets defined by non-invasive global mapping improve rates of acute atrial fibrillation termination?\n* Does such a personalized ablation approach reduce arrhythmia recurrence rates? Researchers will compare the results of the personalized ablation approach with comparable patients that had undergone a conventional \"empirical\" ablation approach (pulmonary vein isolation).\n\nParticipants will:\n\n* Undergo a personalized catheter ablation approach employing both a non-invasive global mapping system and a conventional intracardiac mapping system\n* Visit the clinic 3, 6 and 12 months after ablation for clinical follow-up\n* Schedule a telephone visit 9 and 24 months after ablation for clinical follow-up",[73],"Atrial Fibrillation (AF)",[75,76,77,78,79,80,81],"Atrial Fibrillation","Catheter Ablation","Non-invasive mapping","Global Mapping","Electrocardiographic Imaging","Body Surface Mapping","Atrial fibrillation drivers","2025-12-25",{"date":84,"type":48},"2026-01-06",{"date":86,"type":22},"2026-01-15",{"date":88,"type":22},"2027-12-31",{"name":54,"class":55},5,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":56},"100502760","microvascular-cardiac-allograft-vasculopathy-trial-100502760","NCT05826444","Microvascular Cardiac Allograft Vasculopathy Trial","Morphological and Functional Phenotype of Isolated Microvascular Cardiac Allograft Vasculopathy in Heart Transplant Recipients","mCAV","Inclusion Criteria:\n\n* able to consent\n* Written consent of the participant after clarification and sufficient time to think about participation\n* heart transplant recipient\n* Indication for routine invasive diagnostics or due to symptoms\n* Exercise tolerant in everyday life - cycling, climbing stairs at least 2 floors at a moderate speed without symptoms of exertion or dyspnea\n\nExclusion Criteria:\n\n* Addiction or other diseases that do not allow the patient to assess the nature and scope as well as possible consequences of the study\n* Patients or their legal guardians who do not sign the declaration of consent or who cannot fully understand it due to a lack of German language skills\n* Pregnant women, breastfeeding women\n* Severe comorbidities affecting the miRNA profile: diabetes mellitus, malignancy, end-stage renal disease with renal replacement therapy\n* Contraindication to the stress test: signs of cardiac decompensation, angina pectoris, dyspnea, hyperthyroidism, GFR \\\u003C30 ml\u002Fmin, peripheral arterial disease, pheochromocytoma, angle-closure glaucoma, prostate adenoma, paroxysmal tachycardia, tachycardia atrial fibrillation\n* Evidence of an acute rejection or local wall motion disturbances in the resting echocardiography",{"count":100,"type":22},50,"The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT).\n\nThe utilized methods include dynamic echocardiography, magnetic resonance imaging, invasive microvascular resistance measurements, histology, cellular calcium-signaling and magnetocardiography as well as molecular genetic expression analysis (miRNA based).",[103],"Cardiac Allograft Vasculopathy",[105,106],"heart transplantation","cardiac allograft vasculopathy","2024-08-08",{"date":109,"type":48},"2024-08-12",{"date":111,"type":48},"2022-10-01",{"date":113,"type":22},"2025-12-31",{"name":54,"class":55},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":68,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100471744","mobile-and-digital-application-in-heart-failure-networks-berlinbrandenburg-100471744","NCT05422859","Mobile and Digital Application in Heart Failure Networks Berlin\u002FBrandenburg","MobiDig","Inclusion Criteria:\n\n* Confirmed diagnosis of heart failure\n* Treatment in a certified Heart Failure Unit center in Berlin or Brandenburg\n* Written informed consent of the participants\n* User of a mobile device with an iOS operating system\n\nExclusion Criteria:\n\n* Addiction or other illnesses that do not allow the participants to assess the nature and scope as well as possible consequences of participation or its scientific evaluation\n* insufficient knowledge of the German language, which is necessary to use the application",{"count":100,"type":22},[70],"The MobiDig trial is designed to evaluate an implementation of a mobile phone application with secondary preventive\u002Frehabilitative modules for patients with heart failure in certified Heart Failure Unit centers in Berlin and Brandenburg.\n\nThe aim is to evaluate the effect on quality of life, symptoms and the course of the disease. In addition, the acceptance, adherence and user behavior as well as the implementation potential for a permanent introduction of the application in national heart failure networks will be analyzed.",[126],"Heart Failure","2024-07-03",{"date":129,"type":48},"2024-07-05",{"date":131,"type":48},"2022-07-01",{"date":133,"type":22},"2025-01-01",{"name":54,"class":55},3,""]